J. Reginster, J. Reginster
Jul 1, 1992
Citations
0
Influential Citations
42
Citations
Journal
Bone
Abstract
Tiludronate, (4-chlorophenylthio) methylene bisphosphonate, is a new bisphosphonate available for clinical investigation. It has been syntbetised and patented by Sanofi Recherche (Montpellier, France) and is chemically characterized by a (Cchlorophenyl)thiomethylene side chain on the carbon atom of the basic P-C-P structure (PM: 362.6) (Fig. 1). The double phosphonate group (P-C-P) on the terminal carbon atom is common to all geminal bisphosphonates and confers binding affinity for calcified bone matrix. Preclinical studies in vitro and in vivo have confirmed a specific antiosteoclastic activity of tiludronate and provide the rationale for its investigational use in metabolic bone diseases characterized by excessive osteoclastic resorption.